Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (END-GAME)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07508345

Acronym

END-GAME

Enrollment

Registered

2026-04-02

Start date

2021-06-04

Completion date

2023-07-31

Last updated

2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GVHD

Brief summary

Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Aged between 18 and 70 years old * First allogeneic hematopoietic stem cell (HSC) transplant for hematological disease * Use of HSCs from bone marrow, peripheral blood, or cord blood * Use of HLA-identical related donors, haploidentical related donors, HLA-identical registry donors, registry donors with mismatches at major HLA loci * Signing of informed consent

Exclusion criteria

* Age \< 18 years or \>70 years * Patients receiving allogeneic HSC transplantation for non-hematologic disease * Second or subsequent allogeneic HSC transplantation

Design outcomes

Primary

Measure	Time frame	Description
Predict the risk of aGvHD onset.	During the 18-month enrollment period, approximately 50 adult patients receiving HSCT are expected to be enrolled.	Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Countries

Italy

Outcome results